

Selecta Biosciences Announces Closing of Initial Public Offering

June 27, 2016 5:28 PM ET

WATERTOWN, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB) today announced the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of \$14.00 per share, before underwriting discounts and commissions. All of the shares of common stock in the offering were sold by Selecta Biosciences. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from the company at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. The company's common stock began trading on the NASDAQ Global Market on Wednesday, June 22, 2016 under the ticker symbol "SELB."

UBS Investment Bank and Stifel acted as joint book-running managers for the offering. Canaccord Genuity and Needham & Company acted as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission.

This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone (888) 827-7275; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email to syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Contact

Stephanie Ascher
Stern Investor Relations, Inc.
+1-212-362-1200
stephanie@sternir.com



Selecta Biosciences Inc